Courses of oral corticosteroids · patients with chronic obstructive pulmonary disease
Self‐management interventions including action plans for exacerbations showed no clear difference in courses of oral steroids compared with usual care (low certainty).
1 finding from 1 review
Mean exacerbations requiring a course of oral corticosteroids · adults and adolescents with asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants experiencing one or more episode requiring treatment with oral steroids · episodic viral wheeze in children
Maintenance LTRA showed no clear difference in number of participants experiencing one or more episode requiring… compared with placebo (moderate certainty).
1 finding from 1 review
Number of participants experiencing one or more episode requiring treatment with oral steroids · episodic viral wheeze in children
Intermittent LTRA showed no clear difference in number of participants experiencing one or more episode requiring… compared with placebo (moderate certainty).
1 finding from 1 review
Mean exacerbations requiring a course of oral corticosteroids · asthmatics with sensitivity to house dust mite
MHRV showed no clear difference in exacerbations needing oral steroids compared with placebo (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy probably leads to lower patients with exacerbations treated with oral steroids compared with current best practice (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · adults with asthma not well controlled on ICS
Single inhaler therapy leads to lower patients with exacerbations treated with oral steroids compared with fixed dose ICS (high certainty).
1 finding from 1 review
Exacerbations requiring oral corticosteroids ‐ adults · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief leads to lower patients with exacerbations requiring oral steroids compared with higher‐dose ICS/LABA + SABA (high certainty).
1 finding from 1 review
OR 0.75 [0.65, 0.87]
9096 participants
High
Moderate exacerbations (course of antibiotics or oral steroids) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists probably leads to lower moderate exacerbations (course of antibiotics or oral steroids) compared with placebo (moderate certainty).
1 finding from 1 review
Relapse · patients with acute asthma
Intramuscular corticosteroids showed no clear difference in relapse compared with oral corticosteroids (low certainty).
3 findings from 1 review
RR 0.94 [0.72, 1.24]
9 studies · 804 participants
Low
RR 0.74 [0.51, 1.07]
7 studies · 742 participants
Moderate
RR 0.99 [0.74, 1.33]
5 studies · 556 participants
Low
Adverse events · patients with acute asthma
Intramuscular corticosteroids showed no clear difference in adverse events compared with oral corticosteroids (low certainty).
1 finding from 1 review
Health outcomes Peak expiratory flow readings (higher readings indicate better peak flow) · patients with acute asthma
1 finding from 1 review
Persistence of symptoms · patients with acute asthma
Intramuscular corticosteroids showed no clear difference in symptom persistence compared with oral corticosteroids (low certainty).
1 finding from 1 review
24‐hour beta agonist use · patients with acute asthma
Intramuscular corticosteroids showed no clear difference in 24‐hour beta agonist use compared with oral corticosteroids (low certainty).
1 finding from 1 review
Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both · patients with chronic obstructive pulmonary disease
It is very uncertain whether once‐daily ICS/LABA combined inhalers changes any COPD exacerbation that requires short‐burst oral corticosteroids… compared with once‐daily LAMA (very low certainty).
1 finding from 1 review
Intervention not reported
Patients with ≥ 1 exacerbations requiring oral corticosteroids Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma
The intervention probably leads to lower patients with ≥ 1 exacerbations requiring oral corticosteroids… (moderate certainty).
1 finding from 1 review
Intervention not reported
Participants with ≥ 1 exacerbation requiring oral corticosteroids Duration of trials: 8 to 24 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in participants with ≥ 1 exacerbation requiring oral corticosteroids… (low certainty).
1 finding from 1 review
Intervention not reported
Patients with ≥ 1 exacerbation requiring oral corticosteroids Duration of trials: 8 to 13 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in patients with ≥ 1 exacerbation requiring oral corticosteroids… (moderate certainty).
1 finding from 1 review
Intervention not reported
Exacerbations requiring oral corticosteroids 48 weeks · adults with asthma
The intervention showed no clear difference in exacerbations requiring oral corticosteroids 48 weeks (moderate certainty).
1 finding from 1 review
Exacerbations (OCS) · adults with asthma not well controlled on ICS
LAMA add‐on leads to lower exacerbations requiring oral corticosteroids (OCS) compared with ICS alone (high certainty).
1 finding from 1 review